secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2023-06-28T23:59:59+00:00
Accession:  0001437749-23-018765
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen reports FY 2023 net loss $59.2M; positive fasedienol, itruvone clinical updates
--------------------------------------------------------------------------------

- Net loss of $59.2M for FY ended March 31, 2023, vs $48.7M prior year; cash $16.6M.
- Positive FDA feedback supports LSAS as primary endpoint for fasedienol Phase 3 FEARLESS program in SAD.
- Successful U.S. Phase 1 study of itruvone (PH10) enables Phase 2B development in MDD; Fast Track granted.
- PH80 nasal spray showed statistically significant reduction in hot flashes vs placebo in Phase 2A (p<.001).
- Company pursuing global partnerships to advance six CNS product candidates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000143774923018765/0001437749-23-018765-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000143774923018765/vtgn20230628_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-018765

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer